GUANGZHOU, China, Jan. 9, 2026 /PRNewswire/ — From March 18 to 31, 2026, the 57th China International Furniture Fair (CIFF Guangzhou 2026) will be held in Guangzhou under the theme CONNECT•CREATE. The Home Furniture Exhibition, as one of the three key exhibitions of CIFF Guangzhou, will take place from March 18 to 21. Spanning 430,000 square meters, it will allow overseas brands, buyers, and designers to engage with China’s supply chain, track global trends, and explore emerging business opportunities.

The upcoming edition will expand its scope with more brands in commercial design, upholstered, dining&living, outdoor furniture, and home décor, reflecting structural shifts in the global furniture market.

CONNECT Global Design, Lifestyle, and Future Trend

Design continues to shape the industry’s future, and CIFF 2026’s East Design Show will span 40,000 square meters, featuring 100+ brands driving soft furnishings innovation.

In response to global demand, the fair will spotlight solutions shaped by evolving lifestyles and demographic shifts. In Area D, curated showcases will highlight age-friendly furniture and smart eldercare solutions from around 150 companies in the Silver Life section, while the Pet Life section will explore design influenced by the growing trend of human–pet co-living.

Complementing this, a 10,000-square-meter smart living area will present solutions such as intelligent sleep systems and health monitoring technologies, aligning with growing demand for healthier home environments.

Outdoor living will remain a key focus, with a 50,000-square-meter zone highlighting innovation across the outdoor ecosystem and nature-inspired lifestyles. The home décor segment will emphasize sustainability and cultural heritage, responding to rising interest in environmentally responsible design.

CREATE New Possibilities, Growth, and International Reach

The dining and living room furniture sector will further reinforce the fair’s positioning as “Made for the World.” Covering 120,000 square meters and uniting 800+ manufacturers, the showcase will highlight supply chain efficiency and design-driven manufacturing. High-end products will demonstrate how advanced production capabilities translate into competitive designs, while dedicated platforms will enable more direct connections between manufacturers and international consumers.

SOFA PLUS will return with more brands, improved navigation, and enhanced services for global audiences, positioning itself as a key gateway for Chinese sofa brands worldwide.

As one of the world’s largest furniture exhibitions, CIFF Guangzhou serves as a key bridge between China and the global furniture industry, delivering tangible value in trade matchmaking and trend insight. Visit https://www.ciff-gz.com/en for more information.

CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ — Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology. This initiative reflects both companies’ commitment to advancing oncology research by integrating complementary strengths across computational design, medicinal chemistry, biology, medical science and preclinical development.

Under the terms of the agreement, Iktos will leverage its AI-driven generative design platform to accelerate the discovery of optimized small-molecule candidates against an undisclosed oncology target. Pierre Fabre Laboratories will contribute its extensive knowledge in oncology research and preclinical development to guide the selection, evaluation, and progression of candidate molecules.

Financial terms of the agreement are not disclosed but include an upfront and several milestone payments.

“This collaboration with Iktos marks an important milestone in our journey to build an AI-powered R&D engine at Pierre Fabre Laboratories” said Audrey Kauffmann, Head of Data Science and Biometry at Pierre Fabre Medical Care R&D. “By integrating Iktos’ generative AI and automated chemistry technologies into our research platforms, we are taking a step toward realizing our data and AI strategy. This cooperation exemplifies our ambition to leverage cutting-edge innovation to improve the quality and probability of success in drug discovery, while accelerating the delivery of meaningful advances for patients in oncology.”

“We are delighted to start a drug discovery collaboration with Iktos”, said Olivier Geneste, Head of Drug Discovery at Pierre Fabre Medical Care R&D. “Thanks to its well-established expertise in generative AI coupled to automated chemistry, we strongly believe that Iktos will help us in accelerating and derisking the discovery of innovative therapeutics targeting a highly valuable oncology target to serve unmet cancer patients’ needs.”

“We are delighted to initiate this collaboration with Pierre Fabre Laboratories, a company with a distinguished track record in oncology,” said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “This collaboration exemplifies the powerful complementarity between Iktos’ generative AI and automated chemistry technologies and Pierre Fabre’s deep scientific and clinical development expertise. Together, we intend to create the optimal framework to rapidly and efficiently progress innovative small-molecule candidates in oncology, with the aim of bringing meaningful therapeutic advances to patients worldwide.”

About the Pierre Fabre Laboratories R&D pipeline:

Pierre Fabre Laboratories has expanded its efforts in precision oncology by adding several assets to its R&D pipeline. PFL-241 and PFL-721, two mutant-selective EGFR inhibitors, are being developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic alterations. The pan-RAF inhibitor exarafenib is being developed to expand targeted therapy options for RAS/RAF-driven solid tumors. Moreover, pre-clinical candidates for various oncology targets are sought to be identified in collaboration with Vernalis Ltd. Furthermore, a collaboration with RedRidge Bio is underway to identify and develop biparatopic antibodies for multiple targets in precision oncology, dermatology, and rare diseases. These new additions to the discovery and clinical development portfolio complement Pierre Fabre Laboratories’ existing precision oncology portfolio targeting BRAF, MEK, HER2, as well as EBV-driven post-transplant lymphoproliferative disorder.

About Pierre Fabre Laboratories

Pierre Fabre Laboratories is the world’s second-largest dermo-cosmetics company and one of Europe’s leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care.   

For over 40 years, Pierre Fabre Laboratories has established itself as an international player in oncology, mastering the entire value chain from R&D to marketing. Its portfolio of oncology specialties covers colorectal, breast, lung and skin cancers, as well as certain hematologic malignancies and precancerous dermatological conditions such as actinic keratosis. In 2024, Pierre Fabre Laboratories’ revenues in oncology came to 520 million euros, 88% of which were generated by international sales, out of a total sales figure of 3.1 billion euros.

Based in southwest France since its creation, Pierre Fabre Laboratories manufactures nearly 90% of its products in France and employs 10,200 people worldwide. In 2024, its R&D budget amounted to 219 million euros, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions. There are currently 10 research and development programs underway dedicated to targeted therapies in oncology.

Pierre Fabre Laboratories’ majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company’s other shareholder. This capital structure guarantees the company’s independence, long-term vision and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world.

Pierre Fabre Laboratories’ CSR policy has been assessed by AFNOR Certification and has been awarded the “Exemplary” level of its CSR label (ISO 26 000 standard for sustainable development).

For more information, visit www.pierre-fabre.com, @Laboratoires Pierre Fabre, @Pierre Fabre Oncology

About Iktos

Founded in 2016, Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in silico, optimized to meet all key success criteria of a discovery project. Through software and strategic collaborations with pharmaceutical companies, Iktos combines AI-driven molecular design with robotic synthesis and biological testing, to accelerate drug discovery. With over 60 successful projects to date, Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. The company completed a €15.5M Series A financing round in 2023, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. In 2024, Iktos acquired Synsight, strengthening its platform with cutting-edge cellular imaging and high-content biological screening capabilities. In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform. For more information, visit Iktos.ai.

Media Contacts

Pierre Fabre Laboratories

Yasmine Benyahia
yasmine.benyahia@pierre-fabre.com 

LAS VEGAS, Jan. 9, 2026 /PRNewswire/ — As the premier global tech event kicking off the new year, CES (Consumer Electronics Show) opened grandly in Las Vegas, bringing together innovative products from thousands of technology companies worldwide. It serves as a key platform for unveiling the latest advancements in future technologies. Making its debut at CES, InfiMotion Technology, a Chinese supplier providing electric drive products, presented its breakthrough EDUs, demonstrating its global innovation capabilities in high-voltage architecture, lightweight materials, and system integration. This marks a significant step in how Chinese smart manufacturing is empowering the global high-end electric vehicle supply chain.

The three products showcased by InfiMotion represent major leaps in material innovation, system integration, high-voltage platform, and efficiency—all designed to empower the next generation of intelligent electric vehicles with exceptional performance and energy economy.

High-Performance Magnesium-Aluminum Alloy Dual-Motor System
Featuring an innovative ultra-lightweight magnesium-aluminum alloy housing, this product delivers 340kW of peak power while weighing only 109.5 kg, achieving a power density of 3.1 kW/kg. Already in mass production and deployed in models such as the Galaxy M9 and Lynk & Co 900, it incorporates torque vectoring control to enable a “waltz-style tank turn.”

900V High-Performance Coaxial Dual E-Drive with Magnesium Alloy Housing
Using a coaxial planetary configuration, this product achieves 92.4% CLTC efficiency at operating voltages above 750V, with a power density breakthrough of 5.69 kW/kg. With magnesium alloy, its weight reduces by 30%. InfiMotion’s proprietary deep oil-cooling technology for both stator and rotor enhances thermal performance, enabling over 80 consecutive full-throttle accelerations without performance degradation.

Ultra-Integrated 12-in-1 Domain Control E-Drive
By integrating 12 core modules including the motor, reducer, MCU, VCU, BMS, DC-DC, etc., this 400V IGBT-based EDU achieves 90% CLTC efficiency with a total weight under 79.8 kg. This solution is already in use in the Geely Galaxy E5.

As a global technology partner rooted in China, InfiMotion has established an end-to-end system from R&D to mass production delivery, and is collaborating closely with mainstream and luxury automotive brands worldwide to shape the future of electric mobility.

About InfiMotion Technology
InfiMotion Technology is positioned as a full-stack electric drive component and system solution provider, with comprehensive R&D and manufacturing capabilities spanning from components to top-level systems. Its headquarters is located in Wuxi, China, with five intelligent manufacturing bases and six R&D centers worldwide.

BEIJING, Jan. 9, 2026 /PRNewswire/ — iQIYI, China’s leading online entertainment platform, is redefining creative collaboration by integrating AI into the heart of content production. Over the past year, the company has continued to turn innovation into practice, launching two flagship initiatives, the “Beyond Tools, Toward Teammates” AI Short Film Creation Competition and the”Peter Pau × iQIYI AI Theater” Storytelling Lab. These initiatives have brought together more than 2,600 creators from over 30 countries and regions, aiming to connect, support, and uncover the creative voices shaping storytelling in the AI era.

In July 2025, iQIYI launched the “Beyond Tools, Toward Teammates” AI Short Film Creation Competition in partnership with Google and ByteDance’s Volcano Engine, showcasing how AI is reshaping creative expression in filmmaking. Two months later, iQIYI unveiled the “Peter Pau × iQIYI AI Theater” Storytelling Lab, led by Academy Award-winning Cinematographer and Director Mr. Peter Pau. The program cultivates professional filmmakers in AI-powered production, bridging artistic vision with emerging technologies. The selected works from the lab are expected to premiere on the iQIYI platform in Q1 2026.

Through interviews with participating creators, iQIYI found that, despite the rapid and visible advances in AI over the past year, most creators arrived at the same conclusion: while AI is a powerful amplifier of imagination, it can never replace the unique spark of human creativity.

Different Creators, One Shared Curiosity

Youxue CHEN – First-prize Winner of”Beyond Tools, Toward Teammates” AI Short Film Creation Competition

“For me, the value of AI isn’t just about efficiency or lowering costs, it’s making the impossible tangible,” said CHEN, whose film “Happy Land” won first prize. Using AI, CHEN revisited a story he had once shelved for being “too hard to shoot”, discovering new emotional depth through experimentation. “The real challenge wasn’t showcasing AI’s spectacle, but moving the audience. With this work, we found a reliable creative method and that’s just the beginning. We stand at the threshold of a new era, where imagination knows no limits.”

Mario and Linda – Finalist of “Beyond Tools, Toward Teammates” AI Short Film Creation Competition

The Indonesian husband-and-wife team behind “Grow” describes their project as a reflection on life’s journey and resilience. Using AI, they combined emotional storytelling with artistic cinematography. For them, AI wasn’t a replacement but an enabler: “It is a useful tool that helps us bring our creative ideas to life more easily, quickly, and efficiently. It has also empowered parents like us to create from home, surrounded by our children at play, bringing our stories and imagination into the captivating world of cinema.”

Liu ZHENG – Finalist of “Beyond Tools, Toward Teammates” AI Short Film Creation Competition

 “AI isn’t a substitute, it’s a superpower,” said ZHENG, a professional producer. “I used to have vivid images in my mind that I couldn’t bring to life on my own; now, AI has become my most direct translator, turning boundless imagination into reality. Seeing all those prompts evolve into a coherent story and watching the parallel world I envisioned come alive was an unparalleled sense of accomplishment. My goal for 2026 is to take on a new challenge as a producer and create a larger, more ambitious AI-powered film.”

Contact:
iQIYI Press, press@qiyi.com

ISLAMABAD, Jan. 9, 2026 /PRNewswire/ — Mobile-first digital nano-lending platform Daira has entered into a strategic partnership with Infinix Pakistan, itel Pakistan and Tecno Mobile Pakistan to offer Buy Now, Pay Later (BNPL) installment plans for smartphone buyers across the country.

Through this collaboration, consumers can purchase quality smartphones through flexible and responsible installment options, significantly lowering the upfront cost of device ownership. The initiative aims to make smartphone upgrades more accessible, particularly for users seeking affordable pathways to essential digital tools.

The partnership comes at a critical moment in Pakistan’s digital transformation. With nearly half of the country’s mobile users still relying on feature phones, smartphone affordability remains a key barrier to broader digital participation. The initiative closely aligns with the Ministry of IT and Telecommunication Pakistan’s vision for digital inclusion, including the government’s “Smartphone on Installments” program, which seeks to accelerate smartphone adoption and narrow the digital divide.

“We are proud to partner with leading smartphone brands Infinix Pakistan, itel Pakistan and Tecno Mobile Pakistan to offer BNPL installment plans to Pakistani users,” said Sheikh Omer Nasim, CEO of Daira. “Daira’s BNPL model directly supports the national agenda of digital inclusion by enabling wider access to connected devices, fostering greater participation in the digital economy, and empowering users to engage more fully with digital services.”

As one of the few SECP-licensed, digital-only non-bank financial companies (NBFCs) in Pakistan, Daira was launched by Pakistani fintech company Finleap, part of the global fintech group FinVolution (NYSE: FINV).  The platform leverages global best practices and proven financial models to better serve Pakistan’s financially underserved and excluded segments.

Since its establishment in October 2024, Daira has gained strong market traction and user trust, surpassing 1.5 million registered users and disbursing over PKR 3 billion in cumulative loans as of January 2026. In June 2025, the company obtained a Buy Now, Pay Later license, enabling it to further expand into consumer financing.

HONG KONG, Jan. 9, 2026 /PRNewswire/ — Ribo Life Science Co., Ltd. (“Ribo” or the “Company”, stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.

In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company’s capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company’s core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company’s long-term prospects.

Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: “Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo’s journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders.”

Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.

Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTAR^TM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.

The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company’s successful entry into the capital markets.

About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.

For more information, please visit: www.ribolia.com.